mRNA Engineering Redefined
Our Mission
To reduce human suffering at scale, we aim to radically expand the use of mRNA to treat disease by enabling 1000+ new therapies
The Problem
Translation is complex and far from optimized using existing tools
The Solution
RNAV8’s (pronounced “renovate”) toolkit for engineering mRNA provides a competitive advantage in expression tuning and maximization via non-coding sequence optimization
Latest news
DIANT Pharma and RNAV8 Bio Announce Collaboration to Deliver “Design-to-Delivery” mRNA Solutions.
Two experts in genetic medicines, Devan Shah and Michelle Lynn Hall, discuss the recently announced federal funding cuts for mRNA research and what it means for this area of science going forward.
Wacker Biotech announces strategic collaboration with RNAV8 Bio to enhance mRNA therapeutics development.
Devan Shah and Namita Bisaria, experts in the field of RNA therapies, discuss the year ahead in RNA - opportunities, challenges, AI, fundraising, and more.
Get in Touch
We welcome collaborators across pharma, biotech and academia.
